AMED Insider Trading
Insider Ownership Percentage: 2.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Amedisys Share Price & Price History
Current Price: $92.70
Price Change: ▼ Price Decrease of -0.2 (-0.22%)
As of 03/28/2025 05:00 PM ET
Amedisys Insider Trading History
Amedisys Institutional Trading History
Data available starting January 2016
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Read More on Amedisys
Today's Range
Now: $92.70
52 Week Range
Now: $92.70
Volume
221,184 shs
Average Volume
396,120 shs
Market Capitalization
$3.04 billion
P/E Ratio
36.79
Dividend Yield
N/A
Beta
0.76
Who are the major institutional investors of Amedisys?
Which major investors are selling Amedisys stock?
In the last quarter, AMED stock was sold by these institutional investors:
- Westchester Capital Management LLC
- Bank of America Corp DE
- Mackenzie Financial Corp
- Marshall Wace LLP
- SG Americas Securities LLC
- Natixis
- Renaissance Technologies LLC
- FIL Ltd
Which major investors are buying Amedisys stock?
Within the last quarter, AMED stock was acquired by institutional investors including:
- Caption Management LLC
- Norges Bank
- Wealthfront Advisers LLC
- Pentwater Capital Management LP
- Maven Securities LTD
- Balyasny Asset Management L.P.
- Pacer Advisors Inc.
- LMR Partners LLP